Newcastle University, Institute of Neuroscience, Newcastle upon Tyne, UK.
World J Biol Psychiatry. 2013 Apr;14(3):154-219. doi: 10.3109/15622975.2013.770551.
These guidelines are based on a first edition that was published in 2004, and have been edited and updated with the available scientific evidence up to October 2012. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the long-term treatment of bipolar disorder in adults.
Material used for these guidelines are based on a systematic literature search using various data bases. Their scientific rigor was categorised into six levels of evidence (A-F) and different grades of recommendation to ensure practicability were assigned.
Maintenance trial designs are complex and changed fundamentally over time; thus, it is not possible to give an overall recommendation for long-term treatment. Different scenarios have to be examined separately: Prevention of mania, depression, or an episode of any polarity, both in acute responders and in patients treated de novo. Treatment might differ in Bipolar II patients or Rapid cyclers, as well as in special subpopulations. We identified several medications preventive against new manic episodes, whereas the current state of research into the prevention of new depressive episodes is less satisfactory. Lithium continues to be the substance with the broadest base of evidence across treatment scenarios.
Although major advances have been made since the first edition of this guideline in 2004, there are still areas of uncertainty, especially the prevention of depressive episodes and optimal long-term treatment of Bipolar II patients.
本指南基于 2004 年首次发布的版本编辑和更新,内容纳入了截至 2012 年 10 月的所有现有科学证据。本指南旨在系统综述成人双相障碍长期治疗的所有科学证据。
本指南所采用的资料来源于对多个数据库的系统文献检索。按照证据水平(A-F)对其进行分类,并根据实用性对不同推荐级别进行赋值。
维持治疗试验设计复杂,且随着时间的推移发生了根本性的变化;因此,不可能对长期治疗给出总体推荐。不同情况下需分别检查:预防躁狂、抑郁或任何极性的发作,包括急性缓解者和新治疗者。双相 II 型患者或快速循环者以及特殊亚组患者的治疗可能不同。我们确定了几种预防新躁狂发作的药物,而预防新抑郁发作的研究现状不尽如人意。在各种治疗方案中,锂的证据基础仍然最广泛。
自 2004 年首次发布该指南以来,虽然已经取得了重大进展,但仍存在不确定的领域,尤其是预防抑郁发作和优化双相 II 型患者的长期治疗。